Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease

Exclusion Criteria

• •Patients who are:
• •* Receiving or received treatment with an investigational agent within 4 weeks prior to entering the study OR
• •* have not recovered from adverse events due to agents administered more than 4 weeks earlier as determined by the treating physician.
• •Patients with ALT(SGPT) \> 2.5 X upper limit of normal
• •Patients with a creatinine clearance of \< 60 ml/min
• •Patients who have uncontrolled illness including, but not limited to:
• •* Ongoing or active infection
• •* Emergency room admission or hospitalization in the past 14 days
• •* Major surgery in the past 30 days
• •* Medical/psychiatric illness/social situations that would limit compliance with study requirements as determined by the treating physician.
• •Female patients who are pregnant or breast-feeding
• •Patients with active hepatitis B, hepatitis C, or HIV infection
• •Patients with poor cardiac function as defined by an ejection fraction \< 40% are excluded due to potential poor tolerance of the fluid shifts with leukapheresis (only for patients enrolled on second phase of protocol for Leukapheresis).